AGMB
Agomab Therapeutics NV
Key Financials
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/15/2026 | View on SEC |
| SCHEDULE 13G | 5/6/2026 | View on SEC |
| 6-K | 4/24/2026 | View on SEC |
| 20-F | 4/23/2026 | View on SEC |
| SCHEDULE 13G | 4/16/2026 | View on SEC |
| 3 | 3/18/2026 | View on SEC |
| 3 | 3/18/2026 | View on SEC |
| 3 | 3/18/2026 | View on SEC |
| 3 | 3/18/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | AGMB |
| Company Name | Agomab Therapeutics NV |
| CIK | 2020932 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | other |
| Fiscal Year End | 1231 |
| State of Incorporation | C9 |
| Phone | 32 3 302 35 30 |